Vector Smart Object3

It's Time TO CHALLENGE
Our Understanding of TDT

Transfusion-Dependent β-Thalassaemia (TDT)

Is a Severe, Progressive, Genetic Disease That Impacts Patients for Life.1,2

TDT is the most severe form of β-thalassaemia, characterised by severe anaemia and lifelong transfusion dependence which leads to iron overload, and can result in serious comorbidities and reduced survival compared to the general population.1,2,3

Learn More About β-Thalassaemia

Available treatment options for TDT are lifelong supportive therapy with chronic transfusions and iron chelation or allogeneic haematopoietic stem cell transplant (HSCT).1

Patients with TDT require 
lifelong transfusions 
for survival1

See how chronic transfusions enable survival, but can lead to complications like organ damage due to iron overload1

Allogeneic HSCT: a treatment 
option to potentially correct the 
genetic deficiency in TDT1,4,5

Learn about its outcomes, potential benefits and risks, and why it has been mostly limited to paediatric patients with HLA-matched donors1,4,5

TDT can have a 
significant impact on 
quality of life6,7

Understand how ongoing management of TDT and disease complications can impact patients and caregivers6,7

Take the β-Thalassaemia Challenge

Current Thalassaemia International Federation (TIF) treatment guidelines for transfusion-dependent β-thalassaemia (TDT) recommend that:

D.

Current TIF guidelines for TDT recommend lifelong transfusions, typically every 2 to 5 weeks, in patients with Hb levels <7 g/dL on two occasions, >2 weeks apart, or in patients with Hb >7 g/dL who have other clinical symptoms like facial changes, poor growth, fractures, or clinically significant extramedullary haematopoiesis.1

Share:

Register for updates

For more information about upcoming webinars and educational opportunities, sign up today!

Register now